Kayne Anderson Rudnick Investment Management buys $178,446,061 stake in Core Laboratories N.V. (CLB)

Core Laboratories N.V. (CLB) : Kayne Anderson Rudnick Investment Management scooped up 19,231 additional shares in Core Laboratories N.V. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 9, 2016. The investment management firm now holds a total of 1,490,155 shares of Core Laboratories N.V. which is valued at $178,446,061.Core Laboratories N.V. makes up approximately 2.63% of Kayne Anderson Rudnick Investment Management’s portfolio.

Other Hedge Funds, Including , Brave Asset Management Inc sold out all of its stake in CLB during the most recent quarter. The investment firm sold 100 shares of CLB which is valued $11,710.Calvert Investment Management reduced its stake in CLB by selling 37,499 shares or 74.13% in the most recent quarter. The Hedge Fund company now holds 13,087 shares of CLB which is valued at $1,508,146. Core Laboratories N.V. makes up approx 0.08% of Calvert Investment Management’s portfolio. Quantbot Technologies Lp sold out all of its stake in CLB during the most recent quarter. The investment firm sold 9,595 shares of CLB which is valued $1,088,937.Rice Hall James Associates reduced its stake in CLB by selling 595 shares or 2.36% in the most recent quarter. The Hedge Fund company now holds 24,648 shares of CLB which is valued at $2,859,168. Core Laboratories N.V. makes up approx 0.16% of Rice Hall James Associates’s portfolio.Jlb Associates Inc reduced its stake in CLB by selling 1,193 shares or 6.6% in the most recent quarter. The Hedge Fund company now holds 16,873 shares of CLB which is valued at $2,003,163. Core Laboratories N.V. makes up approx 0.55% of Jlb Associates Inc’s portfolio.

Core Laboratories N.V. closed down -0.51 points or -0.43% at $117.64 with 3,81,995 shares getting traded on Wednesday. Post opening the session at $117.44, the shares hit an intraday low of $116 and an intraday high of $117.88 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Core Laboratories N.V. reported $0.35 EPS for the quarter, based on the information available during the earnings call on Jul 20, 2016. Analyst had a consensus estimate of $0.35. The company had revenue of $148.10 million for the quarter, compared to analysts expectations of $146.21 million. The company’s revenue was down -27.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.81 EPS.

Many Wall Street Analysts have commented on Core Laboratories N.V.. JP Morgan Initiated Core Laboratories N.V. on Jun 10, 2016 to “Overweight”, Price Target of the shares are set at $120.

Core Laboratories N.V. (Core Lab) is a provider of proprietary and patented reservoir description production enhancement and reservoir management services to the oil and gas industry. These services and products are directed toward enabling its clients to improve reservoir performance and increase oil and gas recovery from their producing fields. The Company operates in three segments: Reservoir Description Production Enhancement and Reservoir Management. The Company provides analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry.

Leave a Reply

Core Laboratories N.V. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Core Laboratories N.V.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.